Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options.

about

Rapid response of brain metastasis to crizotinib in a patient with KLC1-ALK fusion and MET gene amplification positive non-small cell lung cancer: a case report.Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology.

P2860

Q33728943-B84B5F86-9866-4BEB-8BAF-AA9FACCD2DDA Q47153925-C04C03C0-D1D9-494A-A90F-C7EF06F7D222

P2860

Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options.

Item

http://www.wikidata.org/entity/Q38825099

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Alterations in genes other tha ...... trials and treatment options.

@en

type

Item

label

Alterations in genes other tha ...... trials and treatment options.

@en

prefLabel

Alterations in genes other tha ...... trials and treatment options.

@en

P1476

Alterations in genes other tha ...... trials and treatment options.

@en

P2093

Arpita Desai

http://www.w3.org/2001/XMLSchema#string

Grace K Dy

http://www.w3.org/2001/XMLSchema#string

Smitha P Menon

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

P304

77-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.28092/J.ISSN.2095-3941.2016.0008

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27144064

http://www.w3.org/2001/XMLSchema#string

P932

4850130

http://www.w3.org/2001/XMLSchema#string

Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options.

about

P2860

P2860

Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932